It's really good to see a study spanning a variety of indications for PROSE.
Patient ocular conditions and clinical outcomes using aPROSE scleral device.
To determine the type and distribution of ocular conditions cared for in a clinic dedicated to scleral devices and to report the clinical outcomes afforded by this approach.
Fifty-one charts of patients fitted unilaterally or bilaterally with a scleral device (Prosthetic Replacement of the Ocular Surface Ecosystem - PROSE) in a two year period were retrospectively reviewed. Patient demographics, ocular diagnoses, associated systemic conditions, best corrected visual acuity (BCVA) before and after fitting, Visual Function Questionnaire score (VFQ-25), and ocular surface disease index (OSDI) score were collected.
All 51 patients were successfully wearing the PROSE device for a period of anywhere from weeks to years. The most common reasons for fitting were to relieve symptoms of moderate to severe dry eye syndrome ("DES", n = 25), management of refractive problems ("refractive", n = 23) with keratoconus being the most common (n = 14), and to manage other anomalies ("other", n = 3). Best corrected visual acuity (logMAR) improved with the wearing of the PROSE device for both the DES (17 letters) and the refractive group (10 letters), but not the "other" group. No serious complications were recorded for any of the patients.
The PROSE device is a useful option not only for the management of ocular surface disease and optical imperfections, but also for other ophthalmic conditions. Moderate to severe dry eye was the most common anomaly managed, followed by eyes with irregular corneal astigmatism. DES and refractive patients experienced improvement in visual acuity with wearing of the PROSE device.
Cont Lens Anterior Eye. 2013 Mar 14. pii: S1367-0484(13)00031-3. doi: 10.1016/j.clae.2013.02.004. [Epub ahead of print]
Dimit R, Gire A, Pflugfelder SC, Bergmanson JP.
Alkek Eye Center, Baylor College of Medicine, Houston, TX, USA. Electronic address: firstname.lastname@example.org.